• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Phase 3 results for Merck’s Dulera for the treatment of COPD

Merck has announced results of two Phase 3 clinical studies of Dulera mometasone furoate/formoterol fumarate inhalation aerosol for the treatment of COPD that show statistically significant improvement in lung function in most of the combinations studied and document the incidence of treatment-related adverse events for two dosage strengths. Dulera is approved in the US for the treatment of asthma patients ages 12 and older, and Merck has filed a supplemental NDA for Dulera for the treatment of COPD.

The two studies each evaluated efficacy and safety for two dose strengths, with moderate-to-severe COPD patients receiving either 200 mcg/10 mcg or 400 mcg/10 mcg daily for 26-week periods. Both studies showed significant improvement in lung function for both dose strengths compared to mometasone alone, and one of the studies showed statistically significant improvement in lung function for Dulera compared to formoterol alone. At the thirteen week mark, Dulera demonstrated significant improvement in lung function versus placebo.

After completion of the 26-week study, researchers randomly selected three quarters of the patients randomized to active treatment to participate in a 26-week treatment safety extension. According to Merck, “At 26 weeks, the pooled incidence of treatment-related adverse events for the DULERA 400 mcg/10 mcg, DULERA 200 mcg/10 mcg, mometasone furoate 400 mcg, formoterol 10 mcg, and placebo groups was 7.2 percent, 4.9 percent, 8.0 percent, 7.5 percent, and 5.4 percent, respectively.” Exposure-adjusted rates of serious adverse events for the same groups were 16.8 percent, 12.1 percent, 16.6 percent and 16.2 percent events/100 subject-years, respectively.

No statistically significant difference “in the incidence or nature of adverse events” was observed at 52 weeks compared to 26 weeks. “The majority of treatment-related adverse events were mild to moderate in severity,” notes Merck, with the most common adverse events being oral fungal infection and cataracts and lenticular opacity.

Merck Research Laboratories Executive Director, Global Scientific Affairs, James E. Fish commented, “These investigational studies confirm Merck’s commitment to research in respiratory diseases. We’re excited to see these data for this investigational use of DULERA presented and discussed at CHEST.”

The company quotes a study investigator Dennis E. Doherty, Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at the University of Kentucky as saying, “This is the first presentation of data from these Phase III investigational studies evaluating the efficacy and safety of Dulera in patients 40 years and older with moderate to very severe COPD. It’s important that the scientific community continue evaluating potential treatment options for our patients with COPD.”

Read the Merck press release.

Share

published on October 24, 2011

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews